Claude Fromentin
Aventis Pharma
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Claude Fromentin.
Bioorganic & Medicinal Chemistry Letters | 1999
Alexis Denis; Constantin Agouridas; Jean-Michel Auger; Yannick Benedetti; Alain Bonnefoy; Francois Bretin; Jean-Francois Chantot; Arlette Dussarat; Claude Fromentin; Solange Gouin d'Ambrieres; Sylvette Lachaud; Patrick Laurin; Odile Le Martret; Véronique Loyau; Nicole Tessot; Jean-Marie Pejac; Sébastien Perron
In the search for new ketolides with improved activities against erythromycin-resistant S. pneumoniae and H. influenzae we synthesized a new 11,12 carbamate ketolide substituted by an imidazo-pyridyl side chain: HMR 3647. This compound demonstrated a potent activity against erythromycin susceptible and resistant pathogens, including penicillin G/erythromycin A-resistant S. pneumoniae and H. influenzae. In vivo, HMR 3647 displayed good pharmacokinetic parameters (Cmax = 2.9 microg/ml, bioavailability=49%, AUC0.8 = 17.2 microg.h/l, t1/2=1h) and was shown to have a high therapeutic efficacy in mice infected by various respiratory pathogens, including multi-resistant S. pneumoniae and Gram negative bacteria such as H. influenzae. HMR 3647 appears to be a very promising agent for the treatment of respiratory infections and is currently in clinical trials.
Bioorganic & Medicinal Chemistry Letters | 2000
Alexis Denis; Francois Bretin; Claude Fromentin; A Bonnet; Alain Bonnefoy; Constantin Agouridas; G Piltan
The effect of 2,3 modifications on the antibacterial activity of ketolides was evaluated by introducing substituents in position 2 and converting the C-1, C-2, C-3 beta-keto-ester into stable 2,3 enol-ether or 2,3 anhydro derivatives. Introduction of a fluorine in C-2 is beneficial with regard to the overall antibacterial spectrum whereas the enol-ether and 2,3 unsaturated compounds, as well as the bulky gem dimethyl or 2-chloro derivatives, are less active particularly against erythromycin resistant strains. A 2-fluoro ketolide derivative demonstrates good antibacterial activity and in vivo efficacy against multi-resistant Streptococcus pneumoniae. Compared to azithromycin against Haemophilus influenzae, this compound is equivalent in vitro and slightly more active in vivo. These results demonstrate that within the ketolide class, to retain good antibacterial activity, position 2 needs to remain tetrahedral and tolerates only very small substituents such as fluorine.
Journal of Medicinal Chemistry | 1998
Constantin Agouridas; Alexis Denis; Jean-Michel Auger; Yannick Benedetti; Alain Bonnefoy; Francois Bretin; Jean-Francois Chantot; Arlette Dussarat; Claude Fromentin; Solange Gouin d'Ambrieres; Sylvette Lachaud; Patrick Laurin; Odile Le Martret; and Véronique Loyau; Nicole Tessot
Archive | 2001
Maxime Lampilas; Jozsef Aszodi; David Alan Rowlands; Claude Fromentin
Archive | 2004
Jozsef Aszodi; Claude Fromentin; Maxime Lampilas; David Alan Rowlands
Archive | 2003
Jozsef Aszodi; Claude Fromentin; Maxime Lampilas; David Alan Rowlands
Archive | 2006
Maxime Lampilas; Jozsef Aszodi; David Alan Rowlands; Claude Fromentin
Archive | 2000
Constantin Agouridas; Alexis Denis; Claude Fromentin
Archive | 1999
Constantin Agouridas; Alexis Denis; Claude Fromentin
Archive | 2002
Jozsef Aszodi; Maxime Lampilas; Claude Fromentin; David Alan Rowlands